Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Gresele P et al. | Platelets and asthma. | 1985 | Lancet | pmid:2857402 |
Lenihan DJ et al. | Involvement of platelet activating factor in physiological stress in the lizard, Anolis carolinensis. | 1985 | Comp. Biochem. Physiol. C, Comp. Pharmacol. Toxicol. | pmid:2861063 |
Braquet P et al. | Involvement of platelet activating factor in respiratory anaphylaxis, demonstrated by PAF-acether inhibitor BN 52021. | 1985 | Lancet | pmid:2861423 |
McIntyre TM et al. | Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. | 1985 | J. Clin. Invest. | pmid:2862164 |
Archer CB et al. | Effects of serum albumin, indomethacin and histamine H1-antagonists on Paf-acether-induced inflammatory responses in the skin of experimental animals and man. | 1985 | Br. J. Pharmacol. | pmid:2862936 |
Malone B et al. | Inactivation of platelet activating factor by rabbit platelets. Lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product. | 1985 | J. Biol. Chem. | pmid:3918041 |
Valone FH and Johnson B | Modulation of cytoplasmic calcium in human platelets by the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine. | 1985 | J. Immunol. | pmid:2578151 |
Wal F et al. | PAF-acether may not mediate the third pathway of platelet aggregation since self-desensitization reduces the effects of low thrombin but enhances those of convulxin. | 1985 | Thromb. Haemost. | pmid:3992525 |
Khan SN et al. | Response to platelet-activating factor of platelets from patients with multiple sclerosis. | 1985 | Acta Neurol. Scand. | pmid:3993327 |
Saito K et al. | Determination of AGEPC generated from human neutrophils and rat skin and muscle tissues by a selected ion monitoring technique of GC/MS. | 1985 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2936200 |
Tamargo J et al. | Electrophysiological effects of platelet-activating factor (PAF-acether) in guinea-pig papillary muscles. | 1985 | Eur. J. Pharmacol. | pmid:3996472 |
Hanahan DJ et al. | Platelet-activating factor: a unique lipid chemical mediator. | 1985 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2936201 |
Terashita Z et al. | Is platelet activating factor (PAF) a mediator of endotoxin shock? | 1985 | Eur. J. Pharmacol. | pmid:3996473 |
Inoue K et al. | Activation of guinea pig peritoneal macrophages by platelet-activating factor in free form or incorporated into liposomes. | 1985 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:2936203 |
Benveniste J | Paf-acether (platelet-activating factor). | 1985 | Adv. Prostaglandin Thromboxane Leukot. Res. | pmid:3159192 |
Verstraete M et al. | An overview of antiplatelet and antithrombotic drugs. | 1985 | Haemostasis | pmid:3159632 |
Heymans F et al. | Structure-activity relationship in PAF-acether. 2. rac-1-O-Octadecyl-2-O-acetyl-3-O-[gamma-(dimethylamino)propyl]glycerol . | 1985 | J. Med. Chem. | pmid:4020830 |
Brain SD and Williams TJ | Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. | 1985 | Br. J. Pharmacol. | pmid:2416378 |
Touqui L et al. | 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle. | 1985 | Biochim. Biophys. Acta | pmid:3967037 |
Weber N and Benning H | Ether glycerolipids: novel substrates for studying specificity of enzymes involved in glycerolipid biosynthesis in higher plants. | 1985 | Eur. J. Biochem. | pmid:3967662 |
O'Neill C | Partial characterization of the embryo-derived platelet-activating factor in mice. | 1985 | J. Reprod. Fertil. | pmid:4067921 |
Mallet AI and Cunningham FM | Structural identification of platelet activating factor in psoriatic scale. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3970690 |
Ardaillou N et al. | Vasoconstrictor-evoked prostaglandin synthesis in cultured human mesangial cells. | 1985 | Am. J. Physiol. | pmid:3918460 |
Lee TC | Biosynthesis of platelet activating factor. Substrate specificity of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase in rat spleen microsomes. | 1985 | J. Biol. Chem. | pmid:4030776 |
Wissner A et al. | Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone. | 1985 | J. Med. Chem. | pmid:4032422 |
Pritchard PH et al. | The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease). | 1985 | Blood | pmid:4063532 |
Wissner A et al. | Analogues of platelet activating factor. 3. Replacement of the phosphate moiety with a sulfonylbismethylene group. | 1985 | J. Med. Chem. | pmid:4032438 |
Wimberly HC et al. | Functional and biochemical characterization of immunologically derived equine platelet-activating factor. | 1985 | Vet. Pathol. | pmid:4035942 |
Sugiura T et al. | Transacylation of 1-O-alkyl-SN-glycero-3-phosphocholine (lyso platelet-activating factor) and 1-O-alkenyl-SN-glycero-3-phosphoethanolamine with docosahexaenoic acid (22:6 omega 3). | 1985 | Biochem. Biophys. Res. Commun. | pmid:2935146 |
Fouque F and Vargaftig BB | Adrenaline/PAF acether synergism on human platelets: involvement of Hydergine. | 1985 | J Pharmacol | pmid:4094442 |
Oda M et al. | Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187. | 1985 | J. Immunol. | pmid:3917470 |
Bergelson LD et al. | Influence of platelet activation factor and prostaglandins on cholesterol esterification in human plasma. | 1985 | FEBS Lett. | pmid:4043408 |
Kilpatrick JM and Virella G | Inhibition of platelet-activating factor by rabbit C-reactive protein. | 1985 | Clin. Immunol. Immunopathol. | pmid:4042435 |
O'Flaherty JT | Neutrophil degranulation: evidence pertaining to its mediation by the combined effects of leukotriene B4, platelet-activating factor, and 5-HETE. | 1985 | J. Cell. Physiol. | pmid:2981891 |
Khan SN et al. | Desaggregation of PAF-acether-aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20K proteins. | 1985 | Eur. J. Pharmacol. | pmid:3920056 |
Wasserman SI | The mast cell and theophylline in asthma. | 1985 | Am. J. Med. | pmid:3002176 |
Bushfield M et al. | Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP. | 1985 | Biochem. J. | pmid:3002327 |
Cox CP et al. | VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). | 1984 Mar-Apr | Peptides | pmid:6206481 |
Vemulapalli S et al. | Cardiovascular and renal action of platelet-activating factor in anesthetized dogs. | 1984 Jul-Aug | Hypertension | pmid:6378787 |
Wodzinowska B and Krajewski T | [Role of blood platelets and their membrane in the process of hemostasis]. | 1984 Jan-Feb | Postepy Hig Med Dosw | pmid:6093087 |
Fink KL and Gross RW | Modulation of canine myocardial sarcolemmal membrane fluidity by amphiphilic compounds. | 1984 | Circ. Res. | pmid:6091941 |
Kulikov VI and Bergel'son LD | [Binding of 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine (thrombocyte activating factor) by plasma components. Exchange of the thrombocyte activating factor between lipoproteins and thrombocytes]. | 1984 | Biokhimiia | pmid:6093897 |
Haye B et al. | Interactions between thyreostimulin and PAF-acether on thyroid cell metabolism. | 1984 | Eur. J. Pharmacol. | pmid:6094205 |
Handley DA et al. | Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. | 1984 | Thromb. Haemost. | pmid:6495262 |
Riess H and Hiller E | Heparin and thrombocytopenia. | 1984 | Ann. Intern. Med. | pmid:6497200 |
Blank ML et al. | Conversion of 1-alkyl-2-acetyl-sn-glycerols to platelet activating factor and related phospholipids by rabbit platelets. | 1984 | Biochem. Biophys. Res. Commun. | pmid:6497876 |
Lichey J et al. | Pressure effects and uptake of platelet-activating factor in isolated rat lung. | 1984 | J Appl Physiol Respir Environ Exerc Physiol | pmid:6501025 |
Denburg JA et al. | Platelet activating factor: regulation by mast cells and aspirin. | 1984 | Agents Actions | pmid:6711391 |
Kramer RM et al. | Metabolism of platelet-activating factor in human platelets. Transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. | 1984 | J. Biol. Chem. | pmid:6436245 |
Kornecki E et al. | Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. | 1984 | Science | pmid:6150550 |